Ceramide-Driven Mechanisms in Pulmonary Fibrosis

Area of Science:

• Pulmonary medicine
• Cell biology
• Biochemistry

Background:

• Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited treatment options.
• Dysregulated sphingolipid metabolism, particularly ceramide accumulation, is increasingly recognized as a key factor in fibrosis.
• Ceramide influences critical cellular processes like apoptosis, inflammation, and fibroblast activation, contributing to lung damage.

Purpose of the Study:

• To systematically review ceramide's role in pulmonary fibrosis.
• To explore ceramide's biosynthetic and metabolic pathways, including chain length-specific functions.
• To discuss therapeutic strategies targeting ceramide metabolism for fibrotic lung diseases.

Main Methods:

• This study is a narrative review.
• It systematically summarizes existing literature on ceramide metabolism and its role in pulmonary fibrosis.
• It analyzes the mechanistic functions of ceramide in lung disease pathogenesis.

Main Results:

• Ceramide accumulation is a significant driver of fibrotic pathogenesis in the lungs.
• Specific ceramide chain lengths and the ceramide to S1P rheostat are crucial in regulating fibrotic processes.
• Ceramide contributes to alveolar epithelial cell apoptosis, inflammation, and vascular barrier dysfunction.

Conclusions:

• Targeting ceramide metabolism presents a promising therapeutic avenue for pulmonary fibrosis.
• Inhibitors of acid sphingomyelinase (ASMase) and serine palmitoyltransferase (SPT) are potential treatments.
• Further research is needed for clinical translation of these ceramide-targeting strategies.